Investing.com -- Gain Therapeutics Inc (NASDAQ:GANX)股价下跌11%，此前这家临床阶段生物技术公司宣布计划进行普通股和购买普通股权证的承销公开发行。
该公司专注于开发变构小分子疗法，计划将所得款项用于推进其主要产品候选GT-02287的临床和非临床开发，该产品用于治疗神经退行性疾病，包括GBA1帕金森病，以及用于一般公司用途。
Gain预计将授予承销商30天的期权，以购买额外最多15%的已发行股票和/或权证。Newbridge Securities Corporation担任此次拟议发行的唯一账簿管理人。
发行的最终条款将取决于定价时的市场条件，公司指出，不能保证此次发行是否或何时完成，也不能保证发行的实际规模或条款。
股价下跌反映了市场对公开发行的典型反应，这通常会导致现有股东的股份被稀释。
本文由人工智能协助翻译。更多信息，请参见我们的使用条款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.